Difference between revisions of "Malignant solid neoplasm, NTRK-mutated"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="float:right; margin-right: 5px;" |- |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align=...") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.nejm.org" to "https://www.nejm.org") |
||
| Line 17: | Line 17: | ||
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[ | + | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1714448 Drilon et al. 2018 (LOXO-TRK-14001)] |
|style="background-color:#91cf61"|Phase 1 | |style="background-color:#91cf61"|Phase 1 | ||
|- | |- | ||
| − | |[ | + | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1714448 Drilon et al. 2018 (SCOUT)] |
|style="background-color:#91cf61"|Phase I/II | |style="background-color:#91cf61"|Phase I/II | ||
|- | |- | ||
| − | |[ | + | |[https://www.nejm.org/doi/full/10.1056/NEJMoa1714448 Drilon et al. 2018 (NAVIGATE)] |
|style="background-color:#91cf61"|Phase II | |style="background-color:#91cf61"|Phase II | ||
|- | |- | ||
| Line 38: | Line 38: | ||
<!-- | <!-- | ||
# '''Abstract:''' Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, Demetri GD, El-Deiry WS, Lassen UN, Dowlati A, Brose MS. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.18_suppl.LBA2501 link to abstract] --> | # '''Abstract:''' Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, Demetri GD, El-Deiry WS, Lassen UN, Dowlati A, Brose MS. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.18_suppl.LBA2501 link to abstract] --> | ||
| − | # '''SCOUT; NAVIGATE:''' Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-739. [ | + | # '''SCOUT; NAVIGATE:''' Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-739. [https://www.nejm.org/doi/full/10.1056/NEJMoa1714448 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29466156 PubMed] |
[[Category:NTRK regimens]] | [[Category:NTRK regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Site-agnostic regimens]] | [[Category:Site-agnostic regimens]] | ||
Revision as of 00:48, 7 December 2018
2 regimens on this page
3 variants on this page
|
All lines of therapy
Larotrectinib monotherapy
Regimen
| FDA-recommended dose |
| Study | Evidence |
|---|---|
| Drilon et al. 2018 (LOXO-TRK-14001) | Phase 1 |
| Drilon et al. 2018 (SCOUT) | Phase I/II |
| Drilon et al. 2018 (NAVIGATE) | Phase II |
Note: these three trials are all reported in a single publication; the doses here are the FDA-recommended doses.
Chemotherapy
- Larotrectinib (Vitrakvi) as follows:
- Adults: 100 mg PO BID
- Pediatrics: 100 mg/m2 (maximum dose of 100 mg) PO BID
Continued indefinitely
References
- SCOUT; NAVIGATE: Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018 Feb 22;378(8):731-739. link to original article contains protocol PubMed